<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2412">
  <stage>Registered</stage>
  <submitdate>16/06/2009</submitdate>
  <approvaldate>16/06/2009</approvaldate>
  <nctid>NCT00930514</nctid>
  <trial_identification>
    <studytitle>A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma</studytitle>
    <scientifictitle>A Two Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Rituximab Subcutaneous (SC) Formulation in Patients With Follicular Lymphoma (FL) as Part of Maintenance Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2008-008490-60</secondaryid>
    <secondaryid>BP22333</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma, Follicular</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rituximab
Treatment: drugs - Rituximab
Treatment: drugs - Rituximab
Treatment: drugs - Rituximab
Treatment: drugs - Rituximab

Active Comparator: Rituximab IV 375 mg/m^2 (Stage 1: Cohort A) - 

Active Comparator: Rituximab IV 375 mg/m^2 (Stage 2: Cohort E) - 

Experimental: Rituximab SC 1400 mg (Stage 2: Cohort F) - 

Experimental: Rituximab SC 375 mg/m^2 (Stage 1: Cohort B) - 

Experimental: Rituximab SC 625 mg/m^2 (Stage 1: Cohort C) - 

Experimental: Rituximab SC 800 mg/m^2 (Stage 1: Cohort D) - 


Treatment: drugs: Rituximab
Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.

Treatment: drugs: Rituximab
Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.

Treatment: drugs: Rituximab
Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.

Treatment: drugs: Rituximab
Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.

Treatment: drugs: Rituximab
Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Minimum Observed Plasma Trough Concentration (C trough)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Observed Plasma Concentration (Cmax)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Reach Maximum Observed Plasma Concentration (Tmax)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Decay Half-Life (t1/2)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)</outcome>
      <timepoint>Up to 29 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  CD20-positive follicular non-Hodgkin's lymphoma (NHL)

          -  Documented partial or complete response a the end of induction treatment with
             rituximab

          -  Must have completed induction treatment, and received at least 1 dose of intravenous
             rituximab maintenance treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than and equal to
             (&lt;=) 2

          -  Life expectancy of greater than and equal to (&gt;=) 6 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Histological evidence of transformation of NHL, or types of NHL other than follicular
             lymphoma

          -  Presence or history of central nervous system disease

          -  History of malignancy other than follicular NHL

          -  Recent major surgery (within 4 weeks prior to screening), excluding lymph node biopsy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>281</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital> - Kogarah</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Kurralta Park</hospital>
    <hospital> - Fitzroy</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2139 - Sydney</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>CÃ³rdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ecuador</country>
      <state>Guayaquil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ecuador</country>
      <state>Quito</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City, Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Huddinge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Sundsvall</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Umea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and
      intravenous rituximab in participants with follicular lymphoma. In the first stage,
      participants who have achieved at least a partial response after induction treatment with
      intravenous rituximab will be randomized to one of 3 treatment cohorts, to receive rituximab
      375 milligram per square meter (mg/m^2) intravenously, 375 mg/m^2 subcutaneously or 625
      mg/m^2 subcutaneously, and pharmacokinetics evaluated on an ongoing basis. Upon selection of
      the subcutaneous dose (800 mg/m^2) which results in rituximab trough plasma concentration (C
      trough) values comparable to those achieved with the intravenous formulation, participants in
      the second stage of the study will be randomized to receive either the subcutaneous or
      intravenous formulation to demonstrate comparability of the C trough levels with both routes
      of administration. Maintenance therapy will continue every 2 or 3 months with the
      subcutaneous formulation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00930514</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>